利拉鲁肽副反应对减肥原因的研究。

IF 3.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Jin Yu, Jeongmin Lee, Seung-Hwan Lee, Jae-Hyung Cho, Hun-Sung Kim
{"title":"利拉鲁肽副反应对减肥原因的研究。","authors":"Jin Yu,&nbsp;Jeongmin Lee,&nbsp;Seung-Hwan Lee,&nbsp;Jae-Hyung Cho,&nbsp;Hun-Sung Kim","doi":"10.1155/2022/5201684","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Purpose</i>. Liraglutide is known to have much lower weight loss effects in real clinical fields than in randomized clinical trials because of its side effects (SE) and discomfort associated with injections. This study is aimed at determining whether the side effects of liraglutide affect weight reduction and its maintenance in real-world practice. <i>Methods</i>. Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals. All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included. For an average of 3 and 6 months, weight changes due to the presence or absence of SE and discontinuation (MAIN or STOP) of liraglutide were checked. <i>Results</i>. Only 40.8% (64/157) of the patients remained on liraglutide for 6 months; 14.7% (23/157) maintained the drug despite SEs (MAIN_SE(+)), and 40.1% (63/157) discontinued the drug despite not having SEs (STOP_SE(-)). At 3 months, there was −5.9 ± 0.6<i>%</i>, −7.9 ± 0.9<i>%</i>, −4.5 ± 0.5<i>%</i>, and −3.4 ± 0.6<i>%</i> weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all <i>p</i> &lt; 0.001 compared to the baseline). However, there were no significant differences in the weight loss between the MAIN (<i>p</i> = 0.062) and STOP (<i>p</i> = 0.204) groups. At 6 months, the weight reduction was −2.0 ± 0.5<i>%</i> (<i>p</i> &lt; 0.001) in MAIN_SE(-), −2.2 ± 0.7<i>%</i> (<i>p</i> &lt; 0.005) in MAIN_SE(+), −1.7 ± 0.7<i>%</i> (<i>p</i> &lt; 0.01) in STOP_SE(-), and −2.0 ± 0.6<i>%</i> (<i>p</i> = 0.01) in STOP_SE(+), compared to baseline. SEs also caused no significant differences in weight loss between the MAIN (<i>p</i> = 0.787) and STOP (<i>p</i> = 0.694) groups. <i>Conclusions</i>. Our study confirmed that the side effects of liraglutide did not affect weight reduction. Moreover, in the real world, the continuous rate of liraglutide use is not high, and the weight gradually increases after 3 months. Therefore, in addition to the side effects of liraglutide, the medical staff should consider various factors that affect drug adherence, consider ways to increase compliance, and continue to ensure management so that patients can maintain their weight.</p>\n </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2022 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733986/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Study on Weight Loss Cause as per the Side Effect of Liraglutide\",\"authors\":\"Jin Yu,&nbsp;Jeongmin Lee,&nbsp;Seung-Hwan Lee,&nbsp;Jae-Hyung Cho,&nbsp;Hun-Sung Kim\",\"doi\":\"10.1155/2022/5201684\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><i>Purpose</i>. Liraglutide is known to have much lower weight loss effects in real clinical fields than in randomized clinical trials because of its side effects (SE) and discomfort associated with injections. This study is aimed at determining whether the side effects of liraglutide affect weight reduction and its maintenance in real-world practice. <i>Methods</i>. Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals. All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included. For an average of 3 and 6 months, weight changes due to the presence or absence of SE and discontinuation (MAIN or STOP) of liraglutide were checked. <i>Results</i>. Only 40.8% (64/157) of the patients remained on liraglutide for 6 months; 14.7% (23/157) maintained the drug despite SEs (MAIN_SE(+)), and 40.1% (63/157) discontinued the drug despite not having SEs (STOP_SE(-)). At 3 months, there was −5.9 ± 0.6<i>%</i>, −7.9 ± 0.9<i>%</i>, −4.5 ± 0.5<i>%</i>, and −3.4 ± 0.6<i>%</i> weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all <i>p</i> &lt; 0.001 compared to the baseline). However, there were no significant differences in the weight loss between the MAIN (<i>p</i> = 0.062) and STOP (<i>p</i> = 0.204) groups. At 6 months, the weight reduction was −2.0 ± 0.5<i>%</i> (<i>p</i> &lt; 0.001) in MAIN_SE(-), −2.2 ± 0.7<i>%</i> (<i>p</i> &lt; 0.005) in MAIN_SE(+), −1.7 ± 0.7<i>%</i> (<i>p</i> &lt; 0.01) in STOP_SE(-), and −2.0 ± 0.6<i>%</i> (<i>p</i> = 0.01) in STOP_SE(+), compared to baseline. SEs also caused no significant differences in weight loss between the MAIN (<i>p</i> = 0.787) and STOP (<i>p</i> = 0.694) groups. <i>Conclusions</i>. Our study confirmed that the side effects of liraglutide did not affect weight reduction. Moreover, in the real world, the continuous rate of liraglutide use is not high, and the weight gradually increases after 3 months. Therefore, in addition to the side effects of liraglutide, the medical staff should consider various factors that affect drug adherence, consider ways to increase compliance, and continue to ensure management so that patients can maintain their weight.</p>\\n </div>\",\"PeriodicalId\":9582,\"journal\":{\"name\":\"Cardiovascular Therapeutics\",\"volume\":\"2022 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2022-12-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733986/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2022/5201684\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2022/5201684","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:已知利拉鲁肽在实际临床领域的减肥效果比随机临床试验低得多,因为它的副作用(SE)和注射时的不适。本研究旨在确定利拉鲁肽的副作用是否会影响体重减轻及其在现实生活中的维持。方法:内分泌科医师对两所三级大学附属医院的资料进行回顾性分析。所有在2014年1月至2019年12月期间至少服用过一次利拉鲁肽的患者都被纳入研究。在平均3个月和6个月的时间里,检查由于SE存在或不存在以及利拉鲁肽停药(主要或停止)导致的体重变化。结果:只有40.8%(64/157)的患者坚持使用利拉鲁肽6个月;14.7%(23/157)的患者尽管有SEs (MAIN_SE(+))仍坚持用药,40.1%(63/157)的患者尽管没有SEs (STOP_SE(-))仍停药。3个月时,MAIN_SE(-)、MAIN_SE(+)、STOP_SE(-)和STOP_SE(+)组的体重分别减轻-5.9±0.6%、-7.9±0.9%、-4.5±0.5%和-3.4±0.6%(与基线相比均p < 0.001)。然而,主要组(p = 0.062)和停止组(p = 0.204)之间的体重减轻没有显著差异。6个月时,与基线相比,MAIN_SE(-)组体重减轻-2.0±0.5% (p < 0.001), MAIN_SE(+)组体重减轻-2.2±0.7% (p < 0.005), STOP_SE(-)组体重减轻-1.7±0.7% (p < 0.01), STOP_SE(+)组体重减轻-2.0±0.6% (p = 0.01)。在主要组(p = 0.787)和停止组(p = 0.694)之间,SEs也没有导致体重减轻的显著差异。结论:我们的研究证实利拉鲁肽的副作用不影响减肥。而且,在现实生活中,利拉鲁肽的持续使用率不高,3个月后体重逐渐增加。因此,除了利拉鲁肽的副作用外,医务人员还应考虑影响药物依从性的各种因素,考虑提高依从性的方法,并继续确保管理,使患者能够保持体重。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A Study on Weight Loss Cause as per the Side Effect of Liraglutide

A Study on Weight Loss Cause as per the Side Effect of Liraglutide

Purpose. Liraglutide is known to have much lower weight loss effects in real clinical fields than in randomized clinical trials because of its side effects (SE) and discomfort associated with injections. This study is aimed at determining whether the side effects of liraglutide affect weight reduction and its maintenance in real-world practice. Methods. Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals. All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included. For an average of 3 and 6 months, weight changes due to the presence or absence of SE and discontinuation (MAIN or STOP) of liraglutide were checked. Results. Only 40.8% (64/157) of the patients remained on liraglutide for 6 months; 14.7% (23/157) maintained the drug despite SEs (MAIN_SE(+)), and 40.1% (63/157) discontinued the drug despite not having SEs (STOP_SE(-)). At 3 months, there was −5.9 ± 0.6%, −7.9 ± 0.9%, −4.5 ± 0.5%, and −3.4 ± 0.6% weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all p < 0.001 compared to the baseline). However, there were no significant differences in the weight loss between the MAIN (p = 0.062) and STOP (p = 0.204) groups. At 6 months, the weight reduction was −2.0 ± 0.5% (p < 0.001) in MAIN_SE(-), −2.2 ± 0.7% (p < 0.005) in MAIN_SE(+), −1.7 ± 0.7% (p < 0.01) in STOP_SE(-), and −2.0 ± 0.6% (p = 0.01) in STOP_SE(+), compared to baseline. SEs also caused no significant differences in weight loss between the MAIN (p = 0.787) and STOP (p = 0.694) groups. Conclusions. Our study confirmed that the side effects of liraglutide did not affect weight reduction. Moreover, in the real world, the continuous rate of liraglutide use is not high, and the weight gradually increases after 3 months. Therefore, in addition to the side effects of liraglutide, the medical staff should consider various factors that affect drug adherence, consider ways to increase compliance, and continue to ensure management so that patients can maintain their weight.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Therapeutics
Cardiovascular Therapeutics 医学-心血管系统
CiteScore
5.60
自引率
0.00%
发文量
55
审稿时长
6 months
期刊介绍: Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信